Table 5. Adjusted rate and HRs of mortality by revised CADILLAC risk class.

	Alive	Death	HR (95% CI)	p-value	HR* (95% CI)	p-value
6 months
Low risk (0-2)/intermediate risk (3-5)	285 (40.20)	4 (9.8)	1.0		1.0
High risk (≥ 6)	424 (59.8)	37 (90.2)	6.1 (2.2-17.0)	0.0006	5.5 (2.0-15.5)	0.0012
1 year
Low risk (0-2)/intermediate risk (3-5)	284 (41.5)	5 (7.6)	1.0		1.0
High risk (≥ 6)	400 (58.5)	61 (92.4)	8.3 (3.3-20.6)	< 0.0001	7.5 (3.0-18.8)	< 0.0001
2 year
Low risk (0-2)/intermediate risk (3-5)	281 (42.5)	8 (9.0)	1.0		1.0
High risk (≥ 6)	380 (57.5)	81 (91.0)	7.4 (3.6-15.2)	< 0.0001	6.7 (3.2-14.0)	< 0.0001

CADILLAC, Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications; CI, confidence intervals; HR, Hazard ratios.

* Adjustment for gender, hypertension, diabetes mellitus, dyslipidemia, atrial fibrillation.